1. South Korea Stocks

  2. •

    Consumer non-durables

  3. •

    Beverages: non-alcoholic
NATURECELL Co., Ltd.

NATURECELL Co., Ltd.

KKRX:007390
23,150.00
KRW
-450.00
(-1.91%)
-42.54EPS
1.12TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
736.92
625.15
620.08
497.37
496.81
469.2
409.26
272.91
329.81
336.86
304.83
503.41
321.94
321.61
Basic EPS, GAAP
-88.53
46.73
-27.1
-86.91
-8.41
39.25
16
-308
-519
-108
-184
19.09
-44.07
-42.54
Free Cash Flow per Basic Share
10.72
-4.54
-18.29
-160.95
51.92
57.71
-18.91
-132.77
-171.84
-295.78
-130.01
-25.04
-255.16
-220.6
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
271.76
331.74
602.45
587.61
698.37
759.66
1,338.26
1,024.38
971.55
912.53
957.32
1,004.15
978.19
979.06
Tangible Book Value per Share
271.76
331.74
590.8
531.79
648.68
713.35
1,282.18
971.45
921.76
866.66
915.46
965.1
941.49
942.98
Basic Weighted Avg Shares
40
41
49
54
55
57
56
61
62
63
63
64
64
64
Sales/Revenue/Turnover
29,208
25,355
30,554
26,788
27,215
26,715
23,072
16,720
20,354
21,252
19,351
32,334
20,735
20,717
Operating Margin (%)
3.9
-5.14
-3.81
-18.99
-1.93
4.59
7.63
-38.34
-36.76
-31.51
-52.59
1.87
-17.46
-16.14
Depreciation Expense
283
294
369
522
849
923
1,391
1,559
1,848
1,332
1,751
1,900
1,828
1,851
Net Income, GAAP
-3,509
1,895
-1,335
-4,681
-461
2,235
902
-18,870
-32,031
-6,814
-11,680
1,226
-2,838
-2,741
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.5
- -
- -
Profit Margin (%)
-12.01
7.47
-4.37
-17.47
-1.69
8.37
3.91
-112.86
-157.37
-32.06
-60.36
3.79
-13.69
-13.23
Working Capital
-1,043
3,355
8,300
6,202
10,802
12,857
47,054
35,816
36,323
31,410
36,408
37,916
20,172
19,646
LT Debt
230
1,910
2,384
6,239
1,871
69
1,874
1,869
1,362
680
1,449
1,005
1,827
1,659
Total Equity
10,771
13,749
31,687
31,948
39,482
43,129
81,889
62,682
60,845
57,158
61,419
64,624
63,030
63,086
Return on Invested Capital (%)
- -
- -
- -
- -
- -
2.77
2.66
- -
- -
- -
- -
0.83
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
5.26
1.65
- -
- -
- -
- -
2.12
- -
- -
Return on Common Equity (%)
-36.18
15.46
-5.88
-14.71
-1.29
5.41
1.44
-26.1
-51.86
-11.55
-19.7
1.95
-4.45
-4.33

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
940
5,976
17,947
LT Borrowings
- -
- -
- -
LT Finance Leases
2,037
1,827
1,659
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
64
64
64
Market Capitalization
1,317,697
1,404,684
1,115,371

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
39,478
28,874
40,619
Cash, Cash Equivalents & STI
26,654
16,767
28,338
Accounts Receivable, Net
4,622
4,722
4,442
Inventories
5,751
5,892
6,610
Total Current Liabilities
4,431
8,701
20,973
Payables & Accruals
- -
- -
- -
ST Debt
940
5,976
17,947
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.13%
0.24%
-2.47%
Free Cash Flow
216.73%
178.37%
921.77%
Net Income, GAAP
-305.58%
-75.91%
-331.48%
Sales/Revenue/Turnover
-0.53%
9.68%
-35.87%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,088
9,624
5,818
7,740
32,334
2025
4,078
6,404
3,900
6,353
20,735
2026
4,060
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.6
20.06
-8.4
4.84
19.09
2025
-19.27
-10.37
-19.72
5.27
-44.07
2026
-17.73
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dae-Joong Byun
Full Time Employees
83
Sector
Consumer non-durables
Industry
Beverages: non-alcoholic
Address
10 Gukhoe-daero 76-gil Seoul SL South Korea 150-870
IPO Date
Nov 30, 1992
Website
naturecell.co.kr
Similar Companies
Coca-Cola Company (The) (NYSE:KO)
Celsius Holdings, Inc. (NASDAQ:CELH)
Varun Beverages Ltd. (NSE:VBL)
Monster Beverage Corporation (NASDAQ:MNST)
Anadolu Efes Biracilik ve Malt Sanayii A.S. (BIST:AEFES)
Coca-Cola Icecek A.S. (BIST:CCOLA)
Business
NatureCell Co., Ltd. (007390.KQ) develops and commercializes stem cell-based therapeutics and regenerative medicine products. The company offers core products and services including Cellgram-AMI, an autologous granulocyte colony-stimulating factor-mobilized peripheral blood stem cell therapy for acute myocardial infarction; Cellgram-AMI2, an advanced version for the same indication; NatureCell Cartilage, an allogeneic umbilical cord blood-derived mesenchymal stem cell therapy for knee osteoarthritis; and NatureCell Macular Degeneration Treatment, targeting age-related macular degeneration; as well as stem cell banking services, contract development and manufacturing organization (CDMO) for cell therapies, and research platforms for cell processing and expansion. Founded in 2000 and headquartered in Seongnam, South Korea, NatureCell operates primarily in the biotechnology and regenerative medicine sectors, targeting patients with cardiovascular diseases, orthopedic conditions, and ophthalmologic disorders through clinical-stage pipelines and commercialized treatments in South Korea, with expansion efforts into international markets including clinical trials in the United States and partnerships in Asia. In recent developments within the last two years, the company advanced Phase III trials for Cellgram-AMI2, achieving positive topline results in 2024 for improving left ventricular ejection fraction in heart failure patients post-myocardial infarction; launched commercial sales of NatureCell Cartilage following regulatory approval in South Korea; formed strategic alliances with global biopharma firms for CDMO services and co-development of allogeneic cell therapies; and secured additional funding through equity offerings to support pipeline expansion and manufacturing scale-up.